U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07846176) titled 'Aficamten and Patient-Reported Outcomes in Real-World nHCM' on Sept. 23.
Brief Summary: This multicenter, prospective, observational, real-world clinical study aims to evaluate the efficacy and safety of Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) by prospectively observing changes in symptoms, biomarkers, imaging findings, and adverse reactions, etc. It will also record the dosing regimens at which individual patients achieve steady state, and explore the treatment patterns of Aficamten in Chinese patients with symptomatic nHCM.
Study Start Date: June 01, 2027
Study Type: OBSERVATION...